Thanasis Poullikkas

Mr. Thanasis Poullikkas

Leading Graduate School Doctoral Program in Human Biology, School of Integrative and Global Majors (SIGMA), University of Tsukuba, Tennodai 1-1-1, Tsukuba, Ibaraki 305-8573, Japan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2021 in Antibodies
Verified
Journal Article
Open access
PDF file
LALokesh Agrawal
Lokesh Agrawal
Thanasis PoullikkasThanasis Poullikkas
Thanasis Poullikkas
SEScott Eisenhower
Scott Eisenhower
CMCarlo Monsanto
Carlo Monsanto
RBRanjith Kumar Bakku
Ranjith Kumar Bakku
RKRajkumar Singh Kalra
Rajkumar Singh Kalra
SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is a novel coronavirus for which no known effective antiviral drugs are available. In the present study, to accelerate the discovery of potential drug candidates, bioinformatics-based in silico drug discovery approaches are utilized. We performed multiple sequence alignments of the Spike (S) protein with 75 sequences of different viruses from the Orthocoronavirinae subfamily. This provided us with insights into the evolutionarily conserved domains that can be targeted using drugs or specific antibodies. Further, we analyzed the mechanism of SARS-CoV-2 core proteins, i.e., S and RdRp (RNA-dependent RNA polymerase), to elucidate how the virus infection can utilize hemoglobin to decrease the blood oxygen level. Moreover, after a comprehensive literature survey, more than 60 antiviral drugs were chosen. The candidate drugs were then ranked based on their potential to interact with the Spike and RdRp proteins of SARS-CoV-2. The present multidimensional study further advances our understanding of the novel viral molecular targets and potential of computational approaches for therapeutic assessments. The present study can be a steppingstone in the selection of potential drug candidates to be used either as a treatment or as a reference point when designing a new drug/antibody/inhibitory peptide/vaccine against SARS-CoV-2.

27 September 2020 in arXiv
Verified
Preprint
Open access
PDF file
LALokesh Agrawal
Lokesh Agrawal
Thanasis PoullikkasThanasis Poullikkas
Thanasis Poullikkas
SEScott Eisenhower
Scott Eisenhower
Carlo MonsantoCarlo Monsanto
Carlo Monsanto
RBRanjith Kumar Bakku
Ranjith Kumar Bakku
Due to SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) being a novel virus, there are currently no known effective antiviral drugs capable of slowing its progress. To accelerate the discovery of potential drug candidates, bioinformatics based in silico drug discovery can be applied as a very robust tool. In the present study, more than 60 antiviral drugs already available on the market, were chosen after literature survey. These can be used in clinical trials for the treatment of COVID-19. In this study, these candidate drugs were ranked based on their potential to interact with the Spike protein and RdRp (RNA-dependent RNA polymerase) of SARS-CoV-2. Additionally, the mechanism of their action as well as how the virus infection can utilize Hemoglobin to decrease the oxygen level in blood is explained. Moreover, multiple sequence alignments of the Spike protein with 75 sequences of different viruses from the Orthocoronavirinae subfamily were performed. This gives insight into the evolutionarily conserved domains that can be targeted using drug or antibody treatment. This multidimensional study opens a new layer of understanding about the most effective drug-targetable sites on the Spike protein of SARS-CoV-2.